Back to top

Image: Bigstock

Procter & Gamble (PG) Rises on Q2 Earnings Beat, Ups View

Read MoreHide Full Article

The Procter & Gamble Company (PG - Free Report) , popularly known as P&G, reported second-quarter fiscal 2019 results, wherein top and bottom lines surpassed the Zacks Consensus Estimate. This marked the company’s 15th straight earnings beat. Further, earnings improved year over year while sales remained flat, largely due to adverse currency fluctuations.

Nonetheless, shares of the company rose 3.4% in the pre-market session, driven by its robust view for fiscal 2019. Further, this Zacks Rank #2 (Buy) stock has gained 2.4% in the past year against the industry’s decline of 2.5%.



P&G’s core earnings for the fiscal second quarter were $1.25 per share, up 5% year over year. The company’s earnings beat the Zacks Consensus Estimate of $1.21. The upside was primarily driven by benefits from tax reforms. Currency-neutral core earnings per share (EPS) improved 13%.

Sales in Detail

P&G reported net sales of $17,438 million, which surpassed the Zacks Consensus Estimate of $17,192 million. However, the top line remained nearly flat year over year and was hurt by currency fluctuations to the tune of about 4%.
    
Organically (excluding impacts of acquisitions, divestitures and foreign exchange), revenues grew 4%, driven by 2% rise in shipment volumes. Further, organic sales benefited 1% each from favorable mix and pricing. Notably, all of the business segments, except Grooming, reported organic sales growth.

In the reported quarter, Beauty, and Fabric & Home Care segments registered organic sales growth of 8% and 6%, respectively. Organic sales improved 5% for the Health Care division and 3% for the Baby, Feminine and Family Care segment.  Conversely, organic sales for the Grooming segment dipped 3%.

Net sales for Beauty, and Fabric & Home Care segments grew 4% and 2%, respectively. However, net sales declined 9% at the Grooming segment and 1% at Baby, Feminine & Family Care, while sales for the Health Care segment remained flat year over year.

Margins

Core gross margin decreased 80 basis points (bps) to 49.6%, including nearly 60 bps adverse impact from currency headwinds. On a currency-neutral basis, core gross margin contracted 20 bps due to higher commodity costs, unfavorable mix, innovation reinvestments and other impacts. This was somewhat cushioned by gains from productivity savings and pricing.

Core selling, general and administrative expenses (SG&A) decreased 80 bps (as a percentage of sales) to 26.7%. Currency-neutral core SG&A costs declined 100 bps, driven by savings from overhead, media, agency fee and advertising production cost productivity, as well as benefits of sales leverage.

Core operating margin declined 10 bps to 22.8% while currency-neutral core operating profit margin expanded 80 bps. Currency headwinds impacted core operating margin by 90 bps.

Financials

Procter & Gamble ended the reported quarter with cash and cash equivalents of $3,696 million, long-term debt of $21,514 million, and total shareholders’ equity of $54,443 million.

Cash flow from operating activities amounted to $7,574 million for the first six months of fiscal 2019. Operating cash flow for the fiscal second quarter was $4 billion and free cash flow productivity was 103%.

During the quarter under review, the company returned nearly $2.6 billion to stockholders through dividend payments worth $1.9 billion and share buybacks of roughly $0.8 billion.

The company is on track to surpass its targeted adjusted free cash flow productivity of 90% for fiscal 2019. During the fiscal year, it expects to return cash to shareholders through dividends worth more than $7 billion and share repurchases worth up to $5 billion.

Fiscal 2019 Guidance

Following the strong quarter, the company raised the upper end of the fiscal 2019 organic sales guidance by 1%. Consequently, organic sales for the fiscal year are now estimated to increase 2-4%. The company now expects all-in sales to be down 1% to up 1% in fiscal 2019. Earlier, the company expected all-in sales growth between down 2% and flat. Its all-in sales guidance includes currency impacts of nearly 3-4%. However, acquisitions and divestitures are likely to benefit all-in sales growth for the fiscal year.

However, the company continues to anticipate core EPS growth of 3-8% in fiscal 2019 compared with fiscal 2018 core earnings of $4.22 per share. Earnings guidance includes an adverse impact of nearly $1.4 billion from foreign currency, and escalated commodity and transportation expenses. On an all-in GAAP basis, earnings per share are expected to increase 17-24%.

Don’t Miss These Consumer Staples Stocks

Archer Daniels Midland Company (ADM - Free Report) delivered average positive earnings surprise of 26.9% in the trailing four quarters. The stock presently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

McCormick & Company, Incorporated (MKC - Free Report) , with long-term earnings per share growth rate of 9%, currently sports a Zacks Rank #1.

Church & Dwight Co. Inc. (CHD - Free Report) , with long-term earnings per share growth rate of 10.2%, currently carries a Zacks Rank #2.

Zacks' Top 10 Stocks for 2019

In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?

From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.

This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.

See Stocks Today >>

Published in